Шувалова Ю. А., Мешков А. Н., Каминный А. И., Самко А. Н., Широков Р. О., Стамбольский Д. В., Кухарчук В. В. Ассоциация полиморфизма генов ферментов антиокислительной системы с процессом рестенозирования после коронарного стентирования. Кардиоваскулярная терапия и профилактика. 2008;7(5):36-42.
1. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary – stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994; 331: 496– 501.
2. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994; 331: 489–95.
3. Lowe HC, Oesterle SN, Khachigian LM. Coronary In-Stent Restenosis: Current Status and Future Strategies. JACC 2002; 39: 183–93.
4. Fortuno A, San Jose G, Moreno MU, et al. Oxidative stress and vascular remodelling. Exp Physiol 2005; 90(4): 457–62.
5. Azevedo LC, Pedro MA, Souza LC. Oxidative stress as a signaling mechanism of the vascular response to injury: the redox hypothesis of restenosis. Cardiovasc Res 2000; 47(3): 436–45.
6. Ahn J, Nowell S, McCann SE, et al. Association between catalase phenotype and genotype: modification by epidemiologic factors. Cancer Epidemiol Biomarkers Prev 2006; 15(6): 1217–22.
7. Agachan B, Yilmaz H, Karaali Z, Isbir T. Paraoxonase 55 and 192 polymorphism and its relationship to serum paraoxonase activity and serum lipids in Turkish patients with non-insulin dependent diabetes mellitus. Cell Biochem Funct 2004; 22(3): 163–8.
8. Flekac M, Skrha J, Zidkova K, et al. Paraoxonase 1 gene polymorphisms and enxyme activities in diabetes mellitus. Physiol Res 2007; PMID: 17949258.
9. Bhattacharyya T, Nicholls SJ, Topol EJ, et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 2008; 299(11): 1265–76.
10. Humbert R, Adler DA, Disteche CM, et al. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 1993; 3: 73–6.
11. Tesauro M, Tompson WC, Rogliana P, et al. Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary disease: cleavage of proteins with aspartate vs. glutamate at position 298. Proc Natl Acad Sci USA 2000; 97: 2832–5.
12. Zhou XF, Cui J, DeStefano Al, at al. Polymorphisms in the promoter region of catalase gene and essential hypertension. Dis Markers 2005; 21(1): 3–7.
13. Sanghera DK, Saha N, Aston CE, Kamboh MI. Genetic polymorphism of paraoxonase and the risk of coronary artery disease. Arterioscler Thromb Vasc Biol 1997; 17: 1067–73.
14. Horibe H, Yamada Y, Ichihara S, et al. Genetic risk for restenosis after coronary ballon angioplasty. Aterosclerosis 2004; 174: 181–7.
15. Hibi K, Ishigami T, Tamura K, et al. Endothelial nitric oxide synthase gene polymorphism and acute myocardial infarction. Hypertension 1998; 32: 521–6.
16. Gomma AH, Elrayess MA, Knight CJ, et al. The endothelial nitric oxide synthase (Glu298Asp and -786T>C) gene polymorphism are associated with coronary in-stent restenosis. Eur Heart J 2002; 23: 1955–62.
17. Suzuki T, Okumura K, Sone T, et al. The Glu298Asp polymorphism in endothelial nitric oxide synthase gene is associated with coronary in-stent restenosis. Int J Cardiol 2002; 6: 71–6.
18. Gruentzig AR, King SB 3rd, Schlumpf M, et al. Long-term follow-up after percutaneous transluminal coronary angioplasty. The early Zurich experience. N Engl J Med 1987; 316(18): 1127–32.
19. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning, 2nd edn. 1989. Cold Spring Harbor Laboratory Press, Cold Spring Harbor.
20. Perianayagam MC, Liangos O, Kolyada AY, et al. NADPH oxidase p22phox and catalase gene variants are associated with biomarkers of oxidative stress and adverse outcomes in acute renal failure. J Am Soc Nephrol 2007; 18: 255–63.
21. Leus FR, Wittekoek ME, Prins J, et al. Paraoxonase gene polymorphisms are associated with carotid arterial wall thickness in subjects with familial hypercholesterolemia. Atherosclerosis 2000; 149(2): 371–7.
22. Colombo MG, Paradossi U, Andreassi MG, et al. Endothelial nitric oxide synthase gene polymorphisms and risk of coronary artery disease. Clin Chem 2003; 49: 389–95.
23. Hoffmann R, Mintz GS. Coronary in-stent restenosis – predictors, treatment and prevention. Eur Heart J 2000; 21: 1739–49.
24. Inouye M, Mio T, Sumino K. Link between glycation and lipoperoxidation in red blood cells in diabetes. Clin Chim Acta 1999; 285: 35–44.
25. Garg UC, Hassid A. Nitric oxide – generating vasodilators and 8-bromo-cyclic guanosin monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscule cells. J Clin Invest 1998; 83: 1774–7.
26. Yao SK, Ober JC, Krishnaswami A, et al. Endogenous nitric oxide protects against platelet aggregation and cyclic flow variations in stenosed and endothelium-injured arteries. Circulation 1992; 86: 1302–9.
27. Rios DL, D’Onofrio LO, Cerqueira CC, et al. Paraoxonase 1 gene polymorphisms in angiographically assessed coronary artery disease: evidence for gender interaction among Brazilians. Clin Chem Lab Med 2007; 45(7): 874–8.
28. Roest M, Rodenburg J Wiegman A, et al. Paraoxonase genotype and carotid intima-media thickness in children with familial hypercholesterolemia. Eur J Cardiovasc Prev Rehabil 2006; 13(3): 464–6.
29. Chen Q, Reis SE, Kammerer CM, et al. Association between the severity of angiographic coronary artery disease and paraoxonase gene polymorphisms in the National Heart, Lung and Blood Institute – sponsored Women’s Ischemia Syndrome Evaluation (WISE) study. Am J Hum Genet 2003; 72: 13–22.
